Você está na página 1de 21



Calcium and Phosphate Impact Cardiovascular Risk

Gunnar H. Heine, Masaomi Nangaku, Danilo Fliser Eur Heart J. 2013;34(15):1112-1121.

Abstract and Introduction


Non-traditional risk factors substantially contribute to cardiovascular (CV) disease. A deranged calcium phosphate metabolismfirst identified as a major non-traditional CV risk factor in patients with chronic kidney diseasemay be implicated in development and progression of CV disease even among individuals with intact renal function. This review thus summarizes epidemiological and experimental data on the role of calcium, phosphate, and its major regulating hormonesparathyroid hormone, calcitriol, and fibroblast growth factor 23in CV medicine.

Despite increased awareness for traditional cardiovascular (CV) risk factors,[1] cardiovascular disease (CVD) remains the major cause of death worldwide. It is questionable whether more intense therapy of traditional CV risk factors beyond present treatment targets will reduce CV mortality, since recent large-scale randomized trials failed to provide additional CV benefit by use of combined lipid-lowering agents[2] or by more aggressive treatment of hyperglycaemia[3] and hypertension.[4] Therefore, for residual risk reduction, non-traditional CV risk factors become promising targets. Identification of non-traditional CV risk factors for the general population may start with careful characterization of selected patient cohorts at highest CVD risk, such as chronic kidney disease (CKD) patients, in whom the contribution of non-traditional risk factors to CVD is widely acknowledged.[5] Epidemiological and experimental studies identified a deranged calciumphosphate metabolism as a major non-traditional CV risk factor in CKD patients, as recently summarized.[6] Against this background, the present overview discusses how far calcium, phosphate, and their regulating hormones parathyroid hormone (PTH), active vitamin D (1,25-OH vitamin D or calcitriol), and fibroblast growth factor 23 (FGF-23)may be implicated in CVD in subjects without advanced CKD; studies primarily focussing on CKD patients will only be mentioned when deemed necessary for proper understanding.

Physiological Regulation

As the vast majority of total body calcium is located in the bone, only a small fraction of body calcium is present in the plasma. About one half of plasma calcium circulates as free (ionized) calcium, whereas the other half is bound to proteins (mostly albumin) or complexed with citrate, sulphate, or phosphate. Although ionized calcium thus only represents a very small proportion of total body calcium, its level is closely controlled by the interplay of two hormones, namely PTH and calcitriol (Figure 1): decreasing serum calcium levels induce a rapid PTH secretion from parathyroid cells, which in turn stimulates renal hydroxylation of 25OH vitamin D to calcitriol. While calcitriol triggers intestinal calcium absorption, PTH inhibits renal calcium excretion. Additionally, calcitriol and PTH both stimulate osteoclastic bone resorption, shifting calcium from bone to extracellular fluid. Consequently, serum calcium returns to normal values.[7]

Figure 1.

Physiological regulation of calcium metabolism. Black arrows indicate stimulation; red arrows indicate inhibition. Conversely, hypercalcaemia inhibits PTH secretion via activation of parathyroid calcium-sensing receptors (CaSR), and directly and indirectly (via reduced PTH levels) lowers calcitriol levels. Consequently, intestinal absorption decreases, less calcium leaves the bone, and urinary excretion rises. [7]
Calcium and Cardiovascular Disease: Clinical Evidence

This tight regulation allows keeping the serum-ionized calcium level within a very narrow range (in the absence of endocrinological disease affecting PTH/calcitriol regulation, malignant conditions, or other severe comorbidities). Accordingly, measurements of serum-ionized calcium give only poor information on total body calcium homeostasis: calcium overload may occur in the absence of overt hypercalcaemia. This was impressively illustrated in interventional trials among CKD patients who were randomized to receive either high dosages of calcium salts (acetate or carbonate), or calcium-free medication[8,9] for combating

hyperphosphatemia. Patients receiving calcium salts (containing 1.22.3 g elemental calcium) had a seemingly minor increase in serum calcium of ~0.1 mmol/L. Nonetheless, they experienced a much more pronounced progression of vascular calcification.[8,9] The implications of these studies reach far beyond the field of CKD: in apparently healthy subjects, oral intake of calcium supplements (mostly with a recommended dosage of 5001000 mg elemental calcium) has been propagated as a remedy against osteoporosis. Given that neutral calcium balance has been calculated to occur at intakes of 741 mg/day in healthy subjects,[10] which is below average dietary intake in western societies,[11] any additional high-dosage calcium supplementation may lead to calcium loading and potentially to tissue deposition in the absence of overt hypercalcaemia.[12] In line, such intake of calcium supplements for bone protection has recently been claimed to cause excessive myocardial infarction.[13] Conversely, the notion that plasma levels poorly reflect total body calcium balance is further supported by incongruent findings from cohort studies on the association of plasma calcium and future CV events.[1416]
Calcium and Cardiovascular Disease: Experimental Evidence

Our understanding on the pathophysiological implications of calcium in CVD was revolutionized in the last decade: formerly, it was assumed that, in case of oversaturation, calciumphosphate crystals were passively disposed in the vessel wall and in the myocardium. In striking contrast, recent evidence clearly demonstrates an active contribution of calcium ions to CVD; first, calcium ions stimulate PiT 1 (a type III sodium-dependent phosphate cotransporter) expression by vascular smooth muscle cells (VSMCs), which may allow phosphate ions to accumulate intracellularly[17] (compare ref. [18] for a critical discussion); here, phosphate triggers the development of VSMCs into an osteochondrogenic phenotype (see below). Secondly, calcium induces the release of matrix-vesicle-like structures from viable VSMCs and of apoptotic bodies from apoptotic VSMCs which act as a nucleus for extracellular calciumphosphate precipitation.[19,20] Thirdly, calcium reduces the expression of calcification inhibitors by VSMCs.[20] Recent overview articles reviewed calcium and phosphatemediated vascular calcification in detail.[6,18]

Parathyroid Hormone
While a limited body of experimental data suggested direct effects of PTH on myocardial cells (summarized earlier in this journal[21]), PTH did not induce vascular calcification in experimental studies,[22,23] but rather exerted a protective role.[24] Epidemiologically, it remains unclear whether PTH has any direct CV effect beyond its role in calcium regulation: following a report on an independent association between PTH and left ventricular (LV) mass in cross-sectional analyses,[25] findings from the Uppsala Longitudinal Study of Adult Men claimed that PTH may account for as much as 20% of the population-attributable risk proportion for CV mortality.[26] Two subsequent German studies seemingly confirmed a prognostic implication of elevated PTH in cohorts with a high burden of prevalent CVD.[27,28] In contrast, adjustments for confounders virtually erased the prognostic impact of PTH on CV mortality among elder communing-dwelling men in the Osteoporotic Fractures in Men study[29] and in the Rancho Bernardo study.[30] Associations between PTH and CV death were further challenged by two recent studies among individuals free of CVD at baseline: while elevated PTH predicted incident heart failure[31] and malignant arrhythmia[32] in the Cardiovascular Health Study, it was neither independently associated with allcause or CV death, nor with incident myocardial infarction.[31] Moreover, a nested casecontrol study within the Health Professional Follow-Up study failed to identify PTH as a predictor of incident coronary artery disease. [33] Of note, the existence of various assays for PTH measurements complicates the comparison between different cohort studies.[34] Moreover, in patients with asymptomatic primary hyperparathyroidism, who are chronically exposed to elevated PTH levels, a long-term CV impact of moderately elevated PTH levels has recently been questioned.[35] Even among CKD patients, in whom PTH levels are often more than 10-fold higher than in the general population, high PTH failed to independently predict survival in recent large-scale cohort studies.[36,37] In line, the Kidney Disease: Improving Global Outcomes (KDIGO) foundation's 2009 guidelines on chronic kidney disease mineral and bone disorder (CKDMBD) defined much wider target ranges for PTH in CKD patients than earlier guidelines.[38]

Against this background, the Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) study recruited 3883 dialysis patients with secondary hyperparathyroidism, who were randomized to pharmacological PTH lowering by the CaSR-activator cinacalcet, or to placebo treatment,[39] for evaluating the effects of cinacalcet on mortality and CV events. Full publication of the study results is scheduled for late 2012; in June 2012, the study's sponsor pre-announced that cinacalcet failed to improve the CV outcome. In summary, neither in subjects with intact renal function, nor in CKD patients, firm evidence for a relevant contribution of PTH to CVD exists.

Vitamin D
Beyond its fundamental role in bone metabolism and calcium homeostasis, vitamin D may influence various other medical conditions, including CVD. Vitamin D receptors are found in many tissues, and expression of hundreds of genes may be controlled by vitamin D. Since experimental data suggest that vitamin D might exert a wide range of beneficial functions, vitamin D substitution is presently considered a panacea for prevention and treatment of a broad variety of diseases, including malignant, infectious, and CVD. Such an optimistic view is based on the three fundamental assumptions that: i. ii. iii. Hypovitaminosis D is a common finding in many industrialized countries. Beyond its implication in bone disease and calcium metabolism, hypovitaminosis D substantially contributes to extraosseous ('non-skeletal') co-morbidity. Supplementation with vitamin D has important beneficial 'non-skeletal' effects beyond calcium and bone metabolism.

All three hypotheses are debatable, and we will critically discuss these assumptions in the context of CVD.
Is Hypovitaminosis D a Common Finding in Industrialized Countries?

Despite its denomination, vitamin D should be considered a hormone rather than a vitamin: the term vitamin, in its strict definition, is chosen for those organic chemical compounds that are not synthesized in sufficient amount by an organism, requiring their dietary intake. Instead, humans who are regularly exposed to sunlight synthesize adequate levels of vitamin D: solar ultraviolet B radiation catalyses the conversion of 7-dehydrocholesterol (which is found in ample amounts in the skin and in fat depots) to pre-vitamin D3 (pre-cholecalciferol), which spontaneously isomerizes to vitamin D3 (cholecalciferol). Thus, vitamin D becomes an essential nutrient only in subjects deprived of exposure to sunlight. Unfortunately, few food components contain sufficient vitamin D, namely fish liver (oils), fatty fish, and egg yolks.[4042] Many individuals are nowadays neither regularly exposed to sunlight nor do they eat adequate amounts of vitamin D-containing food. Therefore, fortification of certain food with cholecalciferol [or alternatively with ergocalciferol (vitamin D2)] was propagated. For certain historic reasons, fortification became more popular in the USA than in many European countries. Both cholecalciferol and ergocalciferol are inactive precursors of active vitamin D (1,25-OH vitamin D; calcitriol), and both require hydroxylation at the 25carbon and the 1carbon position. C-25 hydroxylation, which is performed by hepatocytes, is poorly regulated. In contrast, C-1 hydroxylation, which mainly occurs in the kidney, is highly controlled by various regulators ( Figure 2).[40,41]

Figure 2.

Synthesis and metabolism of vitamin D. In case of sufficient exposition to sunlight, vitamin D 3 is synthesized in the skin. Nutrition rich in vitamin D3 comprises fish liver, fish liver oils, fatty fish, and egg yolks. In case of insufficient exposition to sunlight and inadequate intake of vitamin D3-rich nutrition, supplementation with either vitamin D2 or vitamin D3 becomes necessary. Both vitamins D2 and D3 require hydroxylation at the 25-carbon (by CYP2R1, mainly in hepatocytes) and at the 1-carbon position (by CYP27B1, mainly in kidney tubular cells). Only the latter is highly controlled [activation (black arrows) by PTH, inhibition (red arrows) by FGF-23, calcium,

and calcitriol itself]. 1,25-OH vitamin D2 and 1,25-OH vitamin D3 are biologically active; they are finally catabolized into biologically inactive components by CYP24R1. Because of their long half-life, measuring of 25-OH vitamin D has become common practice for the assessment of global vitamin D status.[43] Unless indicated otherwise, most assays measure 25-OH vitamin D derived from ergocalciferol (25-OH vitamin D2) as well as from cholecalciferol (25-OH vitamin D3). 25-OH vitamin D levels below 20 ng/mL have been defined as vitamin D deficiency, and levels between 20 and 30 ng/mL as vitamin D insufficiency,[43] because cohort studies suggested that 25OH vitamin D levels >30 ng/mL are necessary for adequate suppression of PTH secretion,[44] and for optimal intestinal calcium absorption.[45] Of note, both assumptions have been questioned recently.[40,43,46] Moreover, any such fixed cut-off value inevitably ignores seasonal variation in 25-OH vitamin D levels, and it is completely unknown whether those 25-OH vitamin D levels that are adequate for calcium and PTH regulation may differ from 25-OH vitamin D levels optimal in CV physiology. The correct definition of hypovitaminosis D is neither trivial, nor purely academic; any definition of an inappropriately high cut-off value will inevitably oversize the dimension of hypovitaminosis D, label millions of individuals around the globe with a misdiagnosis, and potentially expose these otherwise healthy subjects to unnecessary and possibly harmful supplementation. Collectively, in absence of an unequivocal, biologically, and evidence-based definition of low vitamin D levels, a sound estimation of the prevalence of true hypovitaminosis D is currently not possible.
Does Hypovitaminosis D Substantially Contribute to Extra-skeletal Co-morbidity?

Vitamin D may have multiple roles in CV physiology, since vitamin D receptors are found in the myocardium as well as in vascular cells. Specifically, vitamin D has been reported to suppress the renin aldosteron system,[47] to induce insulin secretion[48] and sensitivity,[49] to possess antihypertrophic activity in the myocardium,[50] to block proliferation of VSMCs,[51] to regulate arterial blood pressure,[52] and to inhibit vascular calcification.[53] Moreover, vitamin D may exert immunoregulatory functions, which may further protect against development and progression of atherosclerotic lesions[54] and vascular calcification.[55] However, in clinical cross-sectional studies, low levels of 25-OH vitamin D were neither independently associated with valvular calcification among 1938 Cardiovascular Health Study participants, [56] nor with mean common carotid intima-media thickness in 654 Rancho Bernardo study participants (notably, measurement of internal carotid intima-media thickness yielded discrepant findings).[57] Nevertheless, most large prospective cohort studies found baseline 25-OH vitamin D levels to predict incident CVD,[58,59] CV,[60] and all-cause mortality[6062] with two notable exceptions.[29,30] Interestingly, the relationship between 25-OH vitamin D and adverse outcome was found to be nonlinear in several cohorts, with very high 25-OH vitamin D levels indicating higher risk rather than optimal protection.[59,62] No observational study can proof causality, and associations of 25-OH vitamin D levels with adverse outcome could reflect residual confounding by unmeasured or poorly measured confounders, despite all efforts of statistical adjustment. Individuals who follow a healthy lifestyle are more likely to take vitamin supplements, and to perform outdoor activities with exposure to sunlight, both resulting in higher 25-OH vitamin levels.[63] Moreover, concerns have been raised that reverse causality may exist: deposition of vitamin D in adipose tissue may contribute to hypovitaminosis D in obese individuals, and subjects with low mobility, severe obesity, and/or chronic pain will abstain from outdoor activities, so that chronic disease might induce, rather than follow, low 25-OH D levels.[63] Therefore, it is mandatory to prove the beneficial role of vitamin D on CVD in prospective interventional trials.
Does Supplementation with Vitamin D Have Important Beneficial Effects Beyond Calcium and Bone Metabolism?

Despite the wealth of epidemiological and experimental data on a beneficial role of vitamin D in CVD, no interventional trial on vitamin D intake with a pre-specified clinical CV primary endpoint has been completed up to now in the general population. Instead, CV outcome data were reported from five interventional trials which primarily aimed to analyse the impact of vitamin D intake on fracture rate,[6466] falls,[67] bone density,[68] and/or total mortality.[64] Two studies randomized patients to vitamin D intake or placebo; the other studies compared vitamin D plus calcium intake to placebo. In these five trials, vitamin D intake ranged from 400 IE daily to 100

000 IE every 4 months, and study size from 191 to 36 282 study participants. Despite their heterogeneity in study design and size, the studies' results were homogenous: no trial found a significant reduction in CV events among subjects randomized to vitamin D supplementation.[6468] Vitamin D proponents have argued that vitamin D dosages in most interventional trials were too low to confer CV benefit. In the largest study, participants randomized to vitamin supplementation received 400 IE cholecalciferol daily, keeping many study participants hypovitaminotic despite being randomized to active treatment.[69] Moreover, study participants were not restricted from taking vitamin D supplements on their own, which may have favoured the null hypothesis. Against this background, two large-scale randomized clinical trials are ongoing that test high-dosage vitamin D supplementation for CVD prevention (Table 1).

Table 1.

Future large-scale randomized trials on vitamin D intake Among CKD patients, a single study specifically analysed CV implications of vitamin D treatment: here, despite experimental data on an antihypertrophic myocardial activity of vitamin D,[50] administration of the active vitamin D compound paricalcitol failed to improve myocardial structure and/or function among 227 patients randomized to paricalcitol or placebo. It remains uncertain whether the relatively short treatment period of 48 weeks, and/or a vitamin D-induced increase in FGF-23 (see below) might have masked the hypothesized beneficial effect of vitamin D.[70] In summary, despite a global hype on beneficial non-skeletal effects, convincing data demonstrating that vitamin D therapy improves CV health are currently lacking. Present guidelines from the Endocrine Society recommend that vitamin D intake should primarily be adapted to needs for skeletal health; they suggest against additional vitamin D supplementation for the purpose of preventing CVD,[43] which is in line with a recent scientific statement from the Institute of Medicine.

Physiological Regulation of Phosphate Metabolism

Average phosphate intake in western societies ranges between 1000 and 1500 mg, depending on food composition. Phosphate-rich nutrition comprises meat, fish, dairy products, and food additives.[71] Intestinal absorption is regulated by calcitriol; in the presence of adequate vitamin D levels, approximately 70% of

ingested phosphates are absorbed.[71] To maintain stable serum phosphate levels, urinary phosphate excretion must be adapted to oral intake and intestinal absorption. It is assumed that, by mechanisms which are still incompletely understood, an increase in serum phosphate induces secretion of FGF23 and PTH, both of which stimulate renal phosphate excretion (Figure 3).

Figure 3.

Physiological regulation of phosphate metabolism. Black arrows indicate stimulation, and red arrows indicate inhibition. Dotted lines indicate hypothetical pathways which await final experimental confirmation. Adapted from Heine, Seiler, Fliser, Nephrology Dialysis Transplantation, Oxford University Press, in press. This tight regulation of phosphate homeostasis necessitates intact kidney function. During the course of kidney function decline in CKD, a loss of filtering nephrons may first be compensated by a PTH- and FGF23 mediated increase in phosphate excretion per single nephron, allowing CKD patients to maintain normal serum

phosphate levels until glomerular filtration rate falls below 30 mL/min.[72] Only if CKD progresses further, overt hyperphosphatemia occurs, and CKD patients with highest serum phosphate levels face worst CV outcome. [73] Although PTH and FGF-23 prevent overt hyperphosphatemia in the absence of CKD, recent evidence suggests that even high-normal phosphate levels predict adverse outcome, which has first been shown among Cholesterol And Recurrent Events (CARE) study participants (all of whom had prevalent coronary artery disease at study initiation),[74] and among Framingham offspring study participants (who were free of CVD at study initiation).[15] Within the last years, numerous additional cohort studies confirmed this association. [75] An increase in phosphate burden has been associated with cardiac valvular disease,[56] with LV hypertrophy (LVH),[76] and most notably with vascular calcification. Similarly as discussed before for calcium, phosphate may actively induce calcification by multiple pathophysiologic pathways:[6,18]

After its intake into VSMCs, phosphate induces transcription of messenger RNAs encoding proteins involved in matrix mineralization and bone formation, while down-regulating VSMC-specific transcription factors. Vascular smooth muscle cells may subsequently transform from a contractile into an osteochondrogenic phenotype, and release matrixvesicle (MV) like structures. Phosphate may induce apoptosis in VSMCs, which subsequently release apoptotic bodies (AB). Matrixvesicle and AB themselves further trigger extracellular calcium crystallization. Phosphate inhibits the transformation of macrophages into vascular osteoclasts, which antagonize vascular calcification by their mineral-resorbing capacity. Phosphate induces the expression of FGF-23.

Most of the aspects are discussed in a separate overview article in this Journal,[106] and the remaining part of our current manuscript focuses on FGF23.

The phosphatonin FGF-23 is a 251-amino acid protein that is mainly synthesized and secreted by osteoblasts.[77] Its secretion may be induced by calcitriol, by PTH, by hyperphosphatemia, and/or by oral phosphate loading. In the kidney, FGF-23 stimulates phosphaturia by reducing expression and activity of sodiumphosphate (NaPi) co-transporters in the proximal tubules,[78] and it lowers calcitriol levels by inhibiting its synthesis and by inducing its degradation. Finally, FGF23 suppresses PTH synthesis in the parathyroid glands. For exerting these physiological functions, FGF-23 binds to FGF-receptors in the presence of membrane-bound Klotho, which serves as a co-receptor. While FGF-receptors are expressed ubiquitously, membrane-bound Klotho is selectively found in kidneys, parathyroid glands, and in the choroid plexus,[79] rendering these organs physiological FGF-23 targets. Similarly to PTH, different assays for measuring FGF-23 exist.[80]
Prognostic Impact of FGF-23 in Cardiovascular Disease

Data on CV implications of FGF-23 first emerged from CKD cohorts: serum levels of FGF23 progressively rise over the spectrum of CKD, aiming to keep serum phosphate within normal ranges despite low glomerular filtration rate.[81,82] Indeed, elevated FGF-23 levels may be the earliest[72] and most pronounced laboratory findings in CKD-MBD.[83] At first glance, the increase in FGF-23 might be considered a beneficial compensatory mechanism, protecting CKD patients against phosphate-induced vascular calcification. However, evidence from two large epidemiological studies, the Chronic Renal Insufficiency Cohort (CRIC)[36] and the Homocysteine in Kidney and End Stage Renal Disease Study (HOST),[37] stand against this assumption. These two studies followed 4978 CKD patients (not requiring dialysis treatment at baseline) for a medium of 3.5 years[36] and 2.9 years,[37] respectively. After adjustment for classical CV risk factors and for traditional CKDMBD markers, mortality of patients in the higher quartiles of baseline FGF-23 was more than two-fold increased compared with patients with lowest FGF-23.[36,37] In line, two studies among dialysis patients yielded similar findings.[83,84] While none of these CKD studies analysed specific causes of death,[36,37,83,84] data on CV events were gathered in HOST study participants.[37] Compared with patients with the lowest FGF-23 levels, patients in the highest quartile of

baseline FGF23 had a univariate hazard ratio of 2.58 for future CV events. In multivariate analysis, high FGF23 remained a significant predictor of CV outcome, while native vitamin D, calcitriol, and PTH did not. [37] Similar results were found in two smaller CKD cohort studies.[85,86] These impressing findings raised the question whether FGF-23 might have a similar prognostic role among subjects without overt CKD. This issue has been addressed by four prospective studies [namely the Cardiovascular Heath Study (CHS),[87] Heart and Soul Study,[88] Health Professionals Follow-up Study (HPFS),[33] and the Women's Health and Aging study (WHAS)[89]] which have been published until July 2012; results from two further studies [the Prevention of Events with Angiotensin Converting Enzyme Inhibition trial (PEACE),[90] and HOM SWEET HOMe study] are presented at international meetings in 2012. As summarized in , these studies showed that elevated FGF-23 levels strongly predicted incident heart failure and CV death among subjects without overt CKD, while atherosclerotic events (namely acute myocardial infarction) were predicted less impressively.
Table 2. Predictive value of FGF23 levels Design Subjects Follow-up (median) Endpoint(s) Predictive values of FGF23



3107 community-living senior citizens

10.5 years

All-cause mortality HF CV event (MI, stroke, CV death)

++ ++ +/ ++ ++ ++ ++

Heart and Soul

POCS 833 patients with stable CAD

6 years

All-cause mortality CV event (MI, HF, stroke/TIA) MI HF Stroke/TIA



1309 patients admitted for elective coronary angiography


Non-haemorrhagic stroke/MI/CV death

1100 patients with stable CAD NCCS and near-normal/normal LV function

5 years

CV death/HF MI Stroke

++ ++



1259 subjects without prevalent CVD

10 years 18 months

Non-fatal MI or fatal CAD Incident CKDa

POCS 701 physically disabled women

Mortality (all cause/cause-specific) Note: Only studies which did not selectively recruit patients with overt chronic kidney disease are listed. NSSC, nested casecontrol study; POCS, prospective observational cohort study; CVD, cardiovascular disease; CAD, coronary artery disease; LV, left ventricular; MI, myocardial infarction; CKD, chronic kidney disease; HF, heart failure; TIA, transient ischaemic attack. Predictive value of FGF-23: 2, no predictive value in univariate analysis; +, predictive value in univariate

analysis; 22, no predictive value after multivariate adjustment; ++, predictive value after multivariate adjustment.

Based on 307 without CKD at baseline.

Is FGF-23 a Marker or a Mediator of Cardiovascular Outcome?

It is controversially discussed in how far FGF-23 actively contributes to CV damage. At first glance, it may be argued that adverse outcome in subjects with elevated FGF23 may fully be explained by its strong association with impaired kidney function and with systemic phosphate burden. In this scenario, FGF-23 would be an innocent bystander that passively mirrors deleterious implications of kidney damage and systemic phosphate burden on CV biology. Although most epidemiological studies aimed to adjust for kidney function and serum phosphate, residual confounding cannot be ruled out: most cohorts used creatinine-based estimation of glomerular filtration rate for quantifying kidney function, which is somewhat imprecise at early stages of CKD; serum phosphate levels have a large biological variability (a feature shared with other CKDMBD parameters),[9193] and a single phosphate measurement is therefore a poor marker of systemic phosphate burden. Alternatively, impaired CV outcome in subjects with elevated FGF-23 might result from reduced synthesis and accelerated degradation of calcitriol. However, as stated above, the cardio- and vasculoprotective implications of vitamin D are still under discussion. In contrast, a direct deleterious effect of FGF-23 on the CV system has long been considered unlikely; although myocardial cells express FGF-receptors, the absence of its co-receptor Klotho seemingly precluded a direct FGF-23 effect. This assumption was recently challenged by Faul et al.,[94] who demonstrated in cellular and murine experiments that FGF-23 induced LVH Klotho-independently. Moreover, they reported FGFreceptor blockers to antagonize uraemia-induced LVH. Of note, Shalhoub et al.[95] very recently failed to reproduce beneficial effects of FGF-23 inhibition on LVH when using FGF-23 antibodies instead of FGF-receptor blockers. Expanding findings from cross-sectional studies,[96,97] Faul[98] supplemented their experimental data with serial echocardiographic studies among CKD patients, in whom elevated FGF-23 levels predicted the development of LVH. Left ventricular hypertrophy predisposes to development of LV dysfunction and congestive heart failure, [99,100] which may link experimental data on FGF-23induced myocardial hypertrophy[94] with clinical evidence for a predictive role of FGF-23 in incident heart failure.[88,90] Further support for an association between elevated FGF23 levels and LV function comes from our HOM SWEET HOMe study, which recruited 1309 patients admitted for elective coronary angiography between May 2007 and June 2010. A total of 1022 out of 1309 patients underwent assessment of LV-function with ventriculography. Cross-sectional data from patients studied before January 2010 were published recently;[101] we now updated these results with data from patients recruited afterwards. Confirming our earlier report,[101] higher FGF-23 levels were associated with impaired LV function, but not with the presence or severity of coronary artery disease (Figure 4).

Figure 4.

FGF-23 serum levels among HOM SWEET HOMe study participants stratified by left-ventricular function (left columns) and by the presence and degree of coronary artery disease (right columns). P-values from ANOVA with test for trend. Updated analysis after inclusion of all 1309 study participants.
FGF-23 and Serum Phosphate: Partners in Crime?

Upon these experimental and clinical data, we hypothesize an interaction between FGF-23 and phosphate in the pathophysiology of CVD (Figure 5). Chronic kidney disease and/or diet-associated chronic phosphate loading directly induce vascular calcification and atherosclerosis. Via vascular stiffening and a subsequent increase in cardiac afterload, calcification contributes to LVH, while atherosclerosis when affecting coronary arteriesmay reduce myocardial oxygen delivery. Moreover, an elevated phosphate burden triggers secretion of FGF-23, which aims to tackle hyperphosphatemia by Klotho-dependent stimulation of phosphaturia, but in parallel activates cardiomyocytes. This may further contribute to LVH development, which in the long run predisposes to LV dysfunction and congestive heart failure.

Figure 5.

Hypothesized interplay of FGF-23 and phosphate in initiation and progression of cardiovascular disease (schematic illustration). (A) An elevated phosphate burden may directly contribute to vascular calcification and to atherogenesis, which impacts cardiac function by increasing left-ventricular afterload and by reducing leftventricular oxygen supply. Furthermore, an elevated phosphate burden may indirectly contribute to cardiac disease by triggering FGF-23 secretion. FGF-23 induces myocardial hypertrophy, which may predispose to leftventricular dysfunction. (BD) Potential implications of therapeutic interventions. While oral phosphate binders decrease both FGF-23 and phosphate burden (Figure 5B), FGF-23 antagonists attenuate FGF-23 signalling on myocardial cells at the expense of reduced renal phosphate excretion, thereby further increasing phosphate burden (Figure 5C). Finally, vitamin D treatment may increase both FGF-23 and phosphate burden, which offsets direct beneficial vascular or myocardial effects of vitamin D (Figure 5D). Black arrows indicate stimulation, and red arrows indicate inhibition. Adapted from Heine, Seiler, Fliser, Nephrology Dialysis Transplantation, Oxford University Press, in press. Future clinical and experimental studies must test this hypothetical concept, before new therapeutic strategies may be propagated in CVD. Such treatment strategies could comprise oral phosphate binders, FGF-23blocking agents, or antagonists of FGF-receptors. Among these, only oral phosphate binders are available at present, and their capacity to reduce serum FGF-23 levels has repeatedly been confirmed.[102104] From a pathophysiological viewpoint, oral phosphate binders may confer broader vasculo- and cardioprotection than FGF-23-blocking agents or FGF-receptor antagonists; as depicted in Figure 5, the latter (seemingly more specific) treatment strategies will antagonist myocardial FGF-23 effects at the expense of a reduced urinary phosphate excretion and a subsequent increase in systemic phosphate burden, [95] whereas use of phosphate binders tackles both systemic phosphate burden and elevated FGF23. Notably, different subtypes of FGFreceptors exist, and a better grasp of organ-specific receptor expression might allow to develop selective inhibitors of cardiac FGF-receptors, which may allow combating FGF-23-induced LVH while leaving phosphaturia unaffected. Finally, this pathophysiological model may help explain why vitamin D did not improve CV outcome in interventional trials; any direct beneficial CV effect of vitamin D supplementation might be offset by an increase in serum phosphate and FGF-23.[105]

Numerous experimental and clinical data allowed to characterize calcium, phosphate, and their regulating enzymes as emerging CV risk factor. Their role in the initiation and progression of CVD is, however, still insufficiently understood. As all components of calciumphosphate metabolism are closely intertwined, any interventional modification of a single factor will inevitably affect all other components. Therefore, results from ongoing interventional trials, such as the 'Finnish Vitamin D Trial' and the 'Vitamin D and Omega-3 Trial', must be awaited before individual components of calciumphosphate metabolism may become targets for CVD prevention or treatment in clinical practice.


Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, Gillespie C, Merritt R, Hu FB. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA 2012;307:12731283. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd., Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr.., Cushman WC, SimonsMorton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:15631574. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:25602572.




Cushman WC, Evans GW, Byington RP, Goff DC Jr.., Grimm RH Jr.., Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:15751585. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011;80:572586. Kendrick J, Chonchol M. The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis 2011;58:826834. Bushinsky DA, Monk RD. Electrolyte quintet: calcium. Lancet 1998;352:306311. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245252. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815 1824.


6. 7. 8. 9.

10. Hunt CD, Johnson LK. Calcium requirements: new estimations for men and women by cross-sectional statistical analyses of calcium balance data from metabolic studies. Am J Clin Nutr 2007;86:1054 1063. 11. Bailey RL, Dodd KW, Goldman JA, Gahche JJ, Dwyer JT, Moshfegh AJ, Sempos CT, Picciano MF. Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr 2010;140:817822. 12. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int 2012;81:11161122. 13. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040. 14. Larsson TE, Olauson H, Hagstrom E, Ingelsson E, Arnlov J, Lind L, Sundstrom J. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 2010;30:333339. 15. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Jr., Gaziano JM, Vasan RS. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879885. 16. Grandi NC, Brenner H, Hahmann H, Wusten B, Marz W, Rothenbacher D, Breitling LP. Calcium, phosphate and the risk of cardiovascular events and all-cause mortality in a population with stable coronary heart disease. Heart 2012;98:926933. 17. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004;66:22932299. 18. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011;109:697711. 19. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15:28572867. 20. Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT, Sidibe A, Schurgers LJ, Skepper JN, Proudfoot D, Mayr M, Shanahan CM. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 2011;109:e1-e12.

21. Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease a review. Eur Heart J 2004;25:17761787. 22. Lomashvili K, Garg P, O'Neill WC. Chemical and hormonal determinants of vascular calcification in vitro. Kidney Int 2006;69:14641470. 23. Jono S, Nishizawa Y, Shioi A, Morii H. Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:11351142. 24. Torres PA, De Broe M. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int 2012;82:1925. 25. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003;24:20542060. 26. Hagstrom E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundstrom J, Melhus H, Held C, Lind L, Michaelsson K, Arnlov J. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009;119:27652771. 27. Grandi NC, Breitling LP, Hahmann H, Wusten B, Marz W, Rothenbacher D, Brenner H. Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease. Heart 2011;97:12151221. 28. Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, Marz W. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010;31:15911598. 29. Cawthon PM, Parimi N, Barrett-Connor E, Laughlin GA, Ensrud KE, Hoffman AR, Shikany JM, Cauley JA, Lane NE, Bauer DC, Orwoll ES, Cummings SR. Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. J Clin Endocrinol Metab 2010;95:46254634. 30. Jassal SK, Chonchol M, von Muhlen D, Smits G, Barrett-Connor E. Vitamin d, parathyroid hormone, and cardiovascular mortality in older adults: the Rancho Bernardo study. Am J Med 2010;123:1114 1120. 31. Kestenbaum B, Katz R, de Boer I, Hoofnagle A, Sarnak MJ, Shlipak MG, Jenny NS, Siscovick DS. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol 2011;58:14331441. 32. Deo R, Katz R, Shlipak MG, Sotoodehnia N, Psaty BM, Sarnak MJ, Fried LF, Chonchol M, de Boer IH, Enquobahrie D, Siscovick D, Kestenbaum B. Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study. Hypertension 2011;58:10211028. 33. Taylor EN, Rimm EB, Stampfer MJ, Curhan GC. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 2011;161:956962. 34. Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int 2010;77:93100. 35. Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med 2011;365:2389 2397. 36. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011;305:24322439. 37. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011;22:19131922.

38. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;76:S1S130. 39. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007;2:898905. 40. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011;364:248254. 41. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266281. 42. Lavie CJ, Lee JH, Milani RV. Vitamin D and cardiovascular disease will it live up to its hype? J Am Coll Cardiol 2011;58:15471556. 43. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:19111930. 44. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997;7:439443. 45. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003;22:142146. 46. Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Engelke JA, Shafer MM. Vitamin D insufficiency: disease or no disease? J Bone Miner Res 2008;23:10521060. 47. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the reninangiotensin system in humans. Hypertension 2010;55:12831288. 48. Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluca HF. Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology 1983;113:15111518. 49. Chiu KC, Chuang LM, Yoon C. The vitamin D receptor polymorphism in the translation initiation codon is a risk factor for insulin resistance in glucose tolerant Caucasians. BMC Med Genet 2001;2:2. 50. Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 2011;124:18381847. 51. Carthy EP, Yamashita W, Hsu A, Ooi BS. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 1989;13(6 Pt 2):954959. 52. Vaidya A, Forman JP. Vitamin D and hypertension: current evidence and future directions. Hypertension 2010;56:774779. 53. Cheng S, Coyne D. Vitamin D and outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 2007;16:7782. 54. Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, Proctor BM, Petty M, Chen Z, Schechtman KB, Bernal-Mizrachi L, Bernal-Mizrachi C. 1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009;120:687698. 55. Li X, Speer MY, Yang H, Bergen J, Giachelli CM. Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb Vasc Biol 2010;30:321326.

56. Linefsky JP, O'Brien KD, Katz R, de Boer IH, Barasch E, Jenny NS, Siscovick DS, Kestenbaum B. Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study. J Am Coll Cardiol 2011;58:291297. 57. Reis JP, von Muhlen D, Michos ED, Miller ER 3rd., Appel LJ, Araneta MR, Barrett-Connor E. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis 2009;207:585 590. 58. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008;168:11741180. 59. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503 511. 60. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168:13401349. 61. de Boer IH, Levin G, Robinson-Cohen C, Biggs ML, Hoofnagle AN, Siscovick DS, Kestenbaum B. Serum 25-hydroxyvitamin d concentration and risk for major clinical disease events in a communitybased population of older adults: a cohort study. Ann Intern Med 2012;156:627634. 62. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168:16291637. 63. Welsh P, Peters MJ, Sattar N. Is vitamin D in rheumatoid arthritis a magic bullet or a mirage? The need to improve the evidence base prior to calls for supplementation. Arthritis Rheum 2011;63:1763 1769. 64. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469. 65. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, Heckbert SR, Johnson KC, Manson JE, Sidney S, Trevisan M. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007;115:846854. 66. Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, Grant AM, Campbell MK, Anderson FH, Cooper C, Francis RM, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). J Clin Endocrinol Metab 2012;97:614622. 67. Prince RL, Austin N, Devine A, Dick IM, Bruce D, Zhu K. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch Intern Med 2008;168:103108. 68. Brazier M, Grados F, Kamel S, Mathieu M, Morel A, Maamer M, Sebert JL, Fardellone P. Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebocontrolled study. Clin Ther 2005;27:18851893. 69. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010;152:315323. 70. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674684.

71. Kestenbaum B. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment. Semin Dial 2007;20:286294. 72. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:13701378. 73. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011;305:11191127. 74. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:26272633. 75. Ellam TJ, Chico TJ. Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 2012;220:310318. 76. Neves KR, Graciolli FG, dos Reis LM, Pasqualucci CA, Moyses RM, Jorgetti V. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004;66:22372244. 77. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:683692. 78. Baum M, Schiavi S, Dwarakanath V, Quigley R. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 2005;68:11481153. 79. Tohyama O, Imura A, Iwano A, Freund JN, Henrissat B, Fujimori T, Nabeshima Y. Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J Biol Chem 2004;279:9777 9784. 80. Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009;76:S34S42. 81. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:22722279. 82. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:22052215. 83. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584592. 84. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009;24:27922796. 85. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010;25:39833989. 86. Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, Mikami S, Inoue K, Shimomura A, Nagasawa Y, Okada N, Tsubakihara Y, Rakugi H, Isaka Y. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 2012;50:1266 1274.

87. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, Shlipak MG. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012;60:200207. 88. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010;152:640648. 89. Semba RD, Fink JC, Sun K, Cappola AR, Dalal M, Crasto C, Ferrucci L, Fried LP. Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin J Am Soc Nephrol 2012;7:8591. 90. Udell JA, O'Donnell T, Morrow D, Jarolim P, Omland T, Sloan S, Pfeffer M, Braunwald E, Sabatine M. Association of fibroblast growth factor (FGF)-23 levels with risk of cardiovascular events in patients with stable coronary aretery disease. J Am Coll Cardiol 2012;59:E1480. 91. Gardham C, Stevens PE, Delaney MP, LeRoux M, Coleman A, Lamb EJ. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 2010;5:12611267. 92. Isakova T, Xie H, Barchi-Chung A, Vargas G, Sowden N, Houston J, Wahl P, Lundquist A, Epstein M, Smith K, Contreras G, Ortega L, Lenz O, Briones P, Egbert P, Ikizler TA, Jueppner H, Wolf M. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 2011;6:26882695. 93. Sardiwal S, Gardham C, Coleman AE, Stevens PE, Delaney MP, Lamb EJ. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int 2012;82:100105. 94. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:43934408. 95. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012;122:25432553. 96. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:25452552. 97. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009;207:546 551. 98. Faul C. Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens 2012;21:369375. 99. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeiffer MA, Re RN, Roccella EJ, Savage D, Shub C. The heart in hypertension. N Engl J Med 1992;327:9981008. 100. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:15571562. 101. Seiler S, Cremers B, Rebling NM, Hornof F, Jeken J, Kersting S, Steimle C, Ege P, Fehrenz M, Rogacev KS, Scheller B, Bohm M, Fliser D, Heine GH. The phosphatonin fibroblast growth factor

23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011;32:26882696. 102. Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, Schiavi SC, Slatapolsky E, Brown AJ. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006;104:p23-p32. 103. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006;69:531537. 104. Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, Shigematsu T. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005;9:336339. 105. Burnett-Bowie SA, Leder BZ, Henao MP, Baldwin CM, Hayden DL, Finkelstein JS. Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clin J Am Soc Nephrol 2012;7:624631. 106. Ketteler M, Wolf M, Hahn K, Ritz E. Phosphate: a novel cardiovascular risk factor. Eur Heart J.

Eur Heart J. 2013;34(15):1112-1121. 2013 Oxford University Press Copyright 2007 European Society of Cardiology. Published by Oxford University Press. All rights reserved.